Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback